Sinopharm seals tightly-priced Panda after two-year hiatus
Sinopharm raised Rmb2.8bn ($396m) from a red Panda bond on Saturday. The state-owned traditional Chinese medicine company switched to a shorter tenor to achieve tight pricing.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org